Wednesday, 23 August 2017

Effect of DMF is colourblind

Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM.Fox RJ, Gold R, Phillips JT, Okwuokenye M, Zhang A, Marantz JL.Neurol Ther. 2017 . doi: 10.1007/s40120-017-0077-5. [Epub ahead of print]

INTRODUCTION:Clinical course and treatment response may vary according to race/ethnicity in multiple sclerosis (MS) patients. Delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) demonstrated significant efficacy and a favorable benefit-risk profile in relapsing-remitting MS (RRMS) patients in the 2-year phase III DEFINE/CONFIRM studies.
METHODS:In this post hoc analysis of integrated data from DEFINE/CONFIRM, we assessed clinical efficacy and safety/tolerability in black, Hispanic, and Asian patients treated with DMF 240 mg twice daily (approved dosage) or placebo. Eligible patients were 18-55 years of age with an Expanded Disability Status Scale score of 0-5.0. In the integrated intention-to-treat population, 769 and 771 patients were treated with DMF or placebo, respectively, of whom 10 and 19 were black, 31 and 23 were Hispanic, and 66 and 70 were Asian.
RESULTS:In the black, Hispanic, and Asian subgroups, DMF was associated with lower annualized relapse rates at 2 years compared with placebo [rate ratio (95% confidence interval (CI)), 0.05 (0.00-1.07); 0.31 (0.10-0.95); and 0.64 (0.30-1.34), respectively]. The percentage of black, Hispanic, and Asian patients with 12-week confirmed disability progression was lower with DMF (43%, 8%, and 20%, respectively) compared with placebo [57%, 30%, and 25%, respectively; hazard ratio (95% CI), 0.53 (0.02-1.39); 0.17 (0.00-0.60); and 0.71 (0.32-1.58), respectively]. The safety/tolerability profile of DMF was generally consistent with that in the overall population of DEFINE/CONFIRM. The incidence of adverse events leading to treatment discontinuation in black, Hispanic, and Asian patients was 2/10, 2/31, and 3/66, respectively, with DMF, and 2/19, 1/23, and 8/70, respectively, with placebo.
CONCLUSION:DMF may be an efficacious treatment with a favorable benefit-risk profile in black, Hispanic, and Asian patients with RRMS. Further clinical studies are needed to characterize differences in MS presentation and treatment outcomes across ethnic and racial groups.


You can all read the conclusions that DMF is effective in people irrespective of their skin colour.. Strange study to do but there you go.

7 comments:

  1. Why are we wasting resources studying useless drugs like DMF?

    ReplyDelete
    Replies
    1. Because at some point (2015), Tecfidera sales were not climbing the way it was anticipated:

      http://www.fiercepharma.com/special-report/9-tecfidera

      Delete
    2. Biogen revenue almost 4 billion dollars for FY2015. Not bad for a useless drug. DMF is used also for psoriasis in Germany so it generates a lot of cash for such an inexpensive drug. Anti-inflammatory property is good for preventing relapses.

      Delete
    3. The author list comprises of the chief investigators of tecfidera trials and biogen employees. They are trying to promote their drug this way.

      Delete
    4. I don't think calling useless is correct. Less useful than Lemtrada or Tysabri? Yes. Safer? Also yes. I agree that stronger treatment is a good thing, and something I hope more people consider. But DMF is better than the injectables, and also better than nothing.

      Delete
  2. Why are you calling DMf useless?

    ReplyDelete
  3. Crikey, that's a really surprising outcome. I mean, I thought Hispanics and Asians were, like, a different species with green blood like Vulcans. This is groundbreaking. Nobel prizes all round.

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.